Market Overview

Teva Says Omacetaxine Mepesuccinate Shows Activity in CML

Related TEVA
Teva Announces UK High Court Gives Positive Judgment In The Company's Patent Case Against AstraZeneca
Notable Hedge Funds Disclose Additions And Reductions To Holdings
Sofinnova Ventures Closes $500M Fund (Fox Business)

Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago. These analyses were derived from data that was submitted to the US Food and Drug Administration as part of a new drug application (NDA) and was recently accepted for review.

Posted-In: News FDA

 

Related Articles (TEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters